QIAGEN Strengthens Growing Portfolio of Applications for Its Digital PCR Platform QIAcuity With New Collaborations
07 January 2022 - 5:30PM
Business Wire
- Expanding range of applications for growing base of QIAcuity
digital PCR instruments
- Two new collaborations: Atila BioSystems expands menu to
non-invasive prenatal testing (NIPT), while Actome partnership
designed to enable for the first time protein analysis using
digital PCR technology
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today
announced new additions to the growing number of applications for
QIAcuity, its ultrasensitive digital PCR (dPCR) platform that has
set new standards by using so-called nanoplates to process samples
in two hours rather than the five hours required by other
systems.
QIAGEN has entered into two new collaborations that extend the
QIAcuity ecosystem:
- A collaboration with Atila BioSystems to provide non-invasive
prenatal testing (NIPT) solutions to QIAGEN’s dPCR franchise. NIPT
requires only a blood sample from the mother, and replaces more
invasive testing methods such as amniocentesis that can endanger
the fetus and mother.
- A co-exclusive licensing and co-marketing agreement with German
life-sciences start-up Actome GmbH extends QIAcuity’s reach beyond
genomics into proteomics, enabling the quantification of proteins
as well as the analyses of interactions between different proteins
and between proteins and target genes.
“QIAcuity is expanding into new research fields as a
cost-effective and very reliable digital PCR system,” said Thomas
Schweins, Senior Vice President, Head of the Life Science Business
Area at QIAGEN. “The partnership with Actome extends for the first
time the use of this technology to protein quantification and
protein-protein interaction. Our aim is to make digital PCR and
QIAcuity the new standard in PCR. This technology is significantly
more robust and precise than traditional real-time PCR. In
particular, it enables the quantification of rare genetic events –
such as cancer mutations – with very high precision and in absolute
terms, even in a high background of wildtype genes. We expect more
than half of all traditional PCR applications to eventually move to
digital PCR.”
QIAcuity disperses a sample over thousands of tiny nanoplate
partitions and then simultaneously reads the reaction in each one.
This enables it to quantify even the faintest signals from DNA and
RNA – and now proteins – as it tests for viruses, bacteria or other
disorders, including rare cancer mutations. Its precision has
already established QIAcuity as a vital tool in testing wastewater
for SARS-CoV-2.
Leveraging QIAGEN’s capabilities in dPCR and also sample
preparation, Atila BioSystems has launched the iSAFE™ Non-Invasive
Prenatal Test Kit for use on QIAcuity in singleton pregnancies. The
Research Use Only test can detect targets that indicate possible
chromosomal anomalies – trisomy 21 associated with Down Syndrome,
trisomy 18 associated with Edwards Syndrome, and trisomy 13
associated with Patau Syndrome and fetal fractions. Processing on
QIAcuity takes only 2.5 hours compared to five hours for rival
devices, and comes with five detection channels, making it the
system with the highest multiplexing capabilities for this
application.
The partnership with Actome involves a co-marketing agreement
and provides QIAGEN with a co-exclusive license for digital PCR
applications to use Actome’s patented Protein-Interaction-Coupling
(PICO)-Technology on QIAcuity as an ultrasensitive method to
measure smallest amounts of proteins and the interaction between
proteins as well as between proteins and genes. The PICO-Technology
translates complex protein status into DNA barcodes that can be
amplified and detected on QIAcuity.
As part of the agreement, QIAGEN has made an undisclosed
investment in Actome. The companies will now jointly develop assays
for protein quantification, which will complement genomic analysis
and help establish a fuller picture of a disease. The technology
has the potential to drive the discovery of new biomarkers and the
development of new drugs and diagnostics. It is a step on the path
to understanding the interactome, all the molecular interactions in
a cell, that contribute to diseases.
For more information, please visit http://www.qiagen.com.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare),
Applied Testing (primarily forensics), Pharma (pharma and biotech
companies) and Academia (life sciences research). As of December
31, 2021, QIAGEN employed more than 6,000 people in over 35
locations worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be
considered forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended. To the
extent that any of the statements contained herein relating to
QIAGEN's products, collaborations markets, strategy or operating
results, including without limitation its expected adjusted net
sales and adjusted diluted earnings results, are forward-looking,
such statements are based on current expectations and assumptions
that involve a number of uncertainties and risks. Such
uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations
(including the effects of currency fluctuations, regulatory
processes and dependence on logistics), variability of operating
results and allocations between customer classes, the commercial
development of markets for our products to customers in academia,
pharma, applied testing and molecular diagnostics; changing
relationships with customers, suppliers and strategic partners;
competition; rapid or unexpected changes in technologies;
fluctuations in demand for QIAGEN's products (including
fluctuations due to general economic conditions, the level and
timing of customers' funding, budgets and other factors); our
ability to obtain regulatory approval of our products; difficulties
in successfully adapting QIAGEN's products to integrated solutions
and producing such products; the ability of QIAGEN to identify and
develop new products and to differentiate and protect our products
from competitors' products; market acceptance of QIAGEN's new
products and the integration of acquired technologies and
businesses. For further information, please refer to the
discussions in reports that QIAGEN has filed with, or furnished to,
the U.S. Securities and Exchange Commission (SEC).
Category: Corporate
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220106005881/en/
QIAGEN: Investor Relations John Gilardi, +49 2103 29
11711 Phoebe Loh, +49 2103 29 11457 ir@QIAGEN.com
Public Relations Thomas Theuringer, +49 2103 29 11826
pr@QIAGEN.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024